^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Cancer

    Related cancers:
    1d
    Research on Comprehensive Pedigree Analysis of the Tumor Microenvironment (ChiCTR2600118636)
    P=N/A, N=785, Shandong Provincial Qianfoshan Hospital; Shandong Provincial Qianfoshan Hospital
    New trial
    1d
    A single-arm, single-center, exploratory study of cetuximab beta combined with definitive chemoradiotherapy for elderly patients with locally advanced unresectable esophageal squamous cell carcinoma (ChiCTR2600118542)
    P=N/A, N=47, Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital
    New trial
    |
    Erbitux (cetuximab)
    1d
    Observations and Efficacy Analysis of Different Treatment Modalities for Unresectable Locally Advanced Esophageal Cancer in the Immunotherapy Era: A Real-World, Multicenter, Retrospective Study (ChiCTR2600118389)
    P=N/A, N=500, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
    New trial • Real-world evidence
    1d
    Prospective Phase II Clinical Study of Neoadjuvant Therapy with Disitamab Vedotin Combined with Radiotherapy, Sintilimab, and Capecitabine for HER2-Overexpressing Locally Advanced Gastric Cancer (ChiCTR2600118406)
    P2, N=35, Recruiting, Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Tyvyt (sintilimab) • capecitabine • Aidixi (disitamab vedotin)
    1d
    A Multicenter, Dual-Cohort Exploratory Clinical Study of Anlotinib Plus Bemelstobart as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma (ChiCTR2600118343)
    P=N/A, N=66, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New trial
    |
    docetaxel • Focus V (anlotinib) • albumin-bound paclitaxel • irinotecan
    1d
    A single-arm phase II clinical study of chemotherapy combined with immunotherapy followed by radiotherapy for residual lesions in oligometastatic esophageal squamous cell carcinoma (ChiCTR2600118288)
    P=N/A, N=30, Recruiting, Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital
    New trial
    1d
    An exploratory study on the combination of evoximab and SKB264 for neoadjuvant therapy of resectable esophageal cancer (ChiCTR2600118276)
    P=N/A, N=30, The Second Affiliated Hospital of Air Force Military Medical University; The Second Affiliated Hospital of Air Force Military Medical University
    New trial
    |
    Jiataile (sacituzumab tirumotecan)
    1d
    Multi-center, Observational Clinical Trial for SDC2 and LIFR Gene Methylation Detection Kit (Fluorescent PCR Method) in Humans (ChiCTR2600118119)
    P=N/A, N=0, Completed, Hubei Cancer Hospital; Chongqing Bohao Diagnostic Technology Co., Ltd
    New trial
    1d
    Efficacy and Safety of Steamed Bread Swallowing for Prevention of Stricture After Extensive Endoscopic Submucosal Dissection of Esophageal Mucosal Lesions: A Prospective, Randomized, Controlled Trial​ (ChiCTR2600118139)
    P=N/A, N=80, Ningbo Medical Center Lihuili Hospital​; Ningbo Medical Center Lihuili Hospital?
    New trial
    1d
    A Prospective, Single-arm, Exploratory Study Protocol of Ipalolituo Weiruili Monoclonal Antibody Injection (QL1706) Combined with Chemotherapy as Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma. (ChiCTR2600118074)
    P=N/A, N=20, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital).; The First Affiliated Hospital of Universi
    New trial
    |
    cisplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    1d
    2138-CL-0101: A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (clinicaltrials.gov)
    P1, N=398, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: Nov 2026 --> May 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CA 19-9 (Cancer antigen 19-9)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • paclitaxel • 5-fluorouracil • capecitabine • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • ASP2138
    1d
    A Prospective Clinical Study to Evaluate the Efficacy and Safety of a Novel Y-shaped Layered Anti-reflux Anastomosis in esophagectomy(YES Trial) (ChiCTR2500114874)
    P=N/A, N=340, Recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University | Not yet recruiting --> Recruiting
    Enrollment open